Evaluate Efficacy and Safety in Japanese Subjects With Type 2 Diabetes Mellitus

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 261 participants.

Also called NCT01294423

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 261 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01294423
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Japan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01294423. Randomized; quadruple masking; primary purpose treatment. Start 2011-02 (registry gives no type); primary completion 2012-03 (actual). Results posted on 2013-08-23.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Evaluate Efficacy and Safety in Japanese Subjects With Type 2 Diabetes Mellitus
Condition
High Blood Sugar
Intervention (Drug)
Dapagliflozin
Intervention (Drug)
Dapagliflozin
Intervention (Drug)
Placebo
Lead sponsor
AstraZeneca (class: industry)
Collaborator
Bristol-Myers Squibb (class: industry)

Record details

Record id
cardio:ct-nct01294423
Content hash
b47afdf3b511e2dcd7d98572001d4d3b8ffa859f538185851f2ec2ae2b4baaba